Class-Wide Analysis of Frizzled-Dishevelled Interactions Using BRET Biosensors Reveals Functional Differences among Receptor Paralogs
Wingless/Int-1 (WNT) signaling is mediated by WNT binding to 10 Frizzleds (FZD<sub>1-10</sub>), which propagate the signal inside the cell by interacting with different transducers, most prominently the phosphoprotein Dishevelled (DVL). Despite recent progress, questions about WNT/FZD selectivity and paralog-dependent differences in the FZD/DVL interaction remain unanswered. Here, we present a class-wide analysis of the FZD/DVL interaction using the DEP domain of DVL as a proxy in bioluminescence resonance energy transfer (BRET) techniques. Most FZDs engage in a constitutive high-affinity interaction with DEP. Stimulation of unimolecular FZD/DEP BRET sensors with different ligands revealed that most paralogs are dynamic in the FZD/DEP interface, showing distinct profiles in terms of ligand selectivity and signal kinetics. This study underlines mechanistic differences in terms of how allosteric communication between FZDs and their main signal transducer DVL occurs. Moreover, the unimolecular sensors represent the first receptor-focused biosensors to surpass the requirements for high-throughput screening, facilitating FZD-targeted drug discovery.
Authors
- Jan Voss (ORCID: https://orcid.org/0000-0003-0595-4607)
- Gunnar Schulte (ORCID: https://orcid.org/0000-0002-2700-7013)
- Lukas Grätz (ORCID: https://orcid.org/0000-0001-6755-0742)
Institutions
- Karolinska Institutet (SE)
Publication Details
- Journal
- ACS Sensors
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1021/acssensors.4c00806
- Citations
- 5
- Primary Topic
- Receptor Mechanisms and Signaling
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- McGill University
- Diamond Light Source
- European Federation of Pharmaceutical Industries and Associations
- European Commission
- Deutsche Forschungsgemeinschaft
- Cancerfonden
- Karolinska Institutet
- Novo Nordisk
- Kungliga Tekniska Högskolan
- Vetenskapsrådet
- Novo Nordisk Fonden
- Innovative Medicines Initiative
- Horizon 2020 Framework Programme